A detailed history of Wells Fargo & Company transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 15,622 shares of KALV stock, worth $139,973. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,622
Previous 15,932 1.95%
Holding current value
$139,973
Previous $187,000 3.74%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$9.46 - $15.39 $2,932 - $4,770
-310 Reduced 1.95%
15,622 $180,000
Q2 2024

Aug 13, 2024

BUY
$10.35 - $12.49 $14,210 - $17,148
1,373 Added 9.43%
15,932 $187,000
Q1 2024

May 10, 2024

BUY
$11.07 - $16.04 $41,268 - $59,797
3,728 Added 34.42%
14,559 $172,000
Q4 2023

Feb 09, 2024

BUY
$7.58 - $12.25 $25,772 - $41,650
3,400 Added 45.75%
10,831 $132,000
Q3 2023

Nov 13, 2023

SELL
$8.95 - $11.35 $28,219 - $35,786
-3,153 Reduced 29.79%
7,431 $71,000
Q2 2023

Aug 15, 2023

BUY
$7.73 - $10.57 $38,858 - $53,135
5,027 Added 90.46%
10,584 $95,000
Q1 2023

May 12, 2023

BUY
$6.3 - $8.39 $27,197 - $36,219
4,317 Added 348.15%
5,557 $43,000
Q4 2022

Feb 13, 2023

SELL
$4.2 - $14.24 $33,688 - $114,219
-8,021 Reduced 86.61%
1,240 $8,000
Q3 2022

Nov 14, 2022

SELL
$9.85 - $16.83 $2,629 - $4,493
-267 Reduced 2.8%
9,261 $134,000
Q2 2022

Aug 12, 2022

SELL
$8.16 - $15.1 $34,582 - $63,993
-4,238 Reduced 30.79%
9,528 $94,000
Q1 2022

May 16, 2022

SELL
$11.2 - $16.97 $86,721 - $131,398
-7,743 Reduced 36.0%
13,766 $203,000
Q4 2021

Feb 14, 2022

SELL
$12.36 - $18.28 $725,371 - $1.07 Million
-58,687 Reduced 73.18%
21,509 $284,000
Q3 2021

Nov 15, 2021

SELL
$17.11 - $24.49 $104,559 - $149,658
-6,111 Reduced 7.08%
80,196 $1.4 Million
Q2 2021

Aug 16, 2021

BUY
$23.12 - $29.91 $1.29 Million - $1.67 Million
55,998 Added 184.76%
86,307 $2.07 Million
Q1 2021

May 13, 2021

SELL
$14.69 - $42.57 $115,580 - $334,940
-7,868 Reduced 20.61%
30,309 $779,000
Q4 2020

Feb 09, 2021

SELL
$12.88 - $19.47 $149,459 - $225,929
-11,604 Reduced 23.31%
38,177 $726,000
Q3 2020

Nov 05, 2020

BUY
$9.83 - $13.99 $20,407 - $29,043
2,076 Added 4.35%
49,781 $627,000
Q2 2020

Aug 13, 2020

BUY
$6.75 - $12.89 $65,522 - $125,123
9,707 Added 25.55%
47,705 $578,000
Q1 2020

May 14, 2020

BUY
$5.8 - $18.56 $220,388 - $705,242
37,998 New
37,998 $292,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $220M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.